Company intelligence / Profile preview

pH Pharma Co., Ltd.

Palo Alto, California, United Stateszoominfo.com ↗

Ownership: Private
Employees: ~27
Development stage: Phase 2

Overview

pH Pharma’s most advanced product candidate is PHP‑201, a Rho kinase inhibitor for normal tension glaucoma. Another Phase 2-ready candidate is a novel neutrophil elastase inhibitor targeting NASH and rare genetic diseases. The company also has an oncology pipeline focused on first-in-class/best-in-class ADC payloads with unique mechanisms of action. Clinical results are not detailed in the available sources but the company is described as "clinical-stage" with at least one program ready for Phase 2 trials[1].

Therapeutic areas: OphthalmologyOncologyGastroenterologyRare Diseases
Modalities: Small molecules (e.g., Rho kinase inhibitors, neutrophil elastase inhibitors)Antibody-drug conjugates (ADCs)
Industry: Biotech

Drug pipeline

1 asset

PHP-201

Phase 2

Indications: Normal tension glaucoma

Partnerships

Immunome Inc.—collaboration and license agreement to develop multiple novel antibody-drug conjugates in oncology, leveraging both companies’ proprietary platforms. Revenue sharing and milestone payments up to $100 million per product are part of the deal structure[1].

Beyond the preview

Go deeper on pH Pharma Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on pH Pharma Co., Ltd..

Explore the full profile